News | June 22, 2022
AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
Bioresource Technology's state of the art manufacturing facility in Weston, Florida
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Expanding diagnostics footprint in East India
Glenmark is the first company in India to market the innovative FDC of Indacaterol
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Subscribe To Our Newsletter & Stay Updated
